Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Provided By GlobeNewswire
Last update: Oct 29, 2024
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skye’s new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skye’s Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skye’s Chief Executive Officer, will continue to serve as a member of the Board.
Read more at globenewswire.com1.57
+0.14 (+9.41%)
Find more stocks in the Stock Screener
SKYE Latest News and Analysis
6 days ago - ChartmillTop stock movements in today's session.Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillTuesday's session: top gainers and losersIntrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
6 days ago - ChartmillThe market is filled with gapping stocks in Tuesday's session.In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
